Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CRINONE

Summary for Tradename: CRINONE

Suppliers: see list3
patent expirations by year for

Pharmacology for Tradename: CRINONE

Drug ClassProgesterone

Clinical Trials for: CRINONE

Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)
Status: Completed Condition: Infertility

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor
Status: Recruiting Condition: Preterm Labor

Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration
Status: Completed Condition: Postmenopausal Endometrium

Comparing IM vs. Vaginal Progesterone for Pre-term Birth
Status: Completed Condition: Infant, Premature; Premature Birth

A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)
Status: Completed Condition: Infertility

Sexual Absorption of Vaginal Progesterone
Status: Completed Condition: Infertility; Pregnancy

Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)
Status: Completed Condition: Infertility

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening
Status: Recruiting Condition: Focus of the Study is to Determine if Oral Progesterone Administration Attenuates Drug-induced QT Interval Lengthening in Women

Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone
Status: Recruiting Condition: Progesterone Supplementation

Oral Progesterone for Prevention of Preterm Birth
Status: Completed Condition: Preterm Birth

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
GEL;VAGINAL020701Jul 31, 1997RXNo5,543,150<disabled><disabled>
Watson Labs
GEL;VAGINAL020701Jul 31, 1997RXYes5,543,150<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology